Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

3.8K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
3.8K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

4.3K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

3.0K
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
3.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and safety of maribavir in Japanese patients with post-transplant cytomegalovirus infections: a phase III study.

International journal of hematologyยท2026
Same author

Case Report: Compromised response of memory-formed bystander T cells after CD19 CAR-T cell therapy following CD20 bispecific antibody therapy.

Frontiers in immunologyยท2026
Same author

Absence of chlamydial infection in ocular adnexal MALT lymphoma based on next-generation sequencing.

Infectious agents and cancerยท2026
Same author

Factors Associated and Survival Outcomes Among Japanese Patients with Solid Cancer Who Developed Deep Vein Thrombosis (DVT).

International journal of general medicineยท2026
Same author

[Sustained hematologic complete response after discontinuation of ropeginterferon alfa-2b in patients with polycythemia vera].

[Rinsho ketsueki] The Japanese journal of clinical hematologyยท2026
Same author

Consensus on the use of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: a modified Delphi survey.

International journal of hematologyยท2026

Related Experiment Video

Updated: Apr 27, 2026

Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia
05:24

Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia

Published on: February 21, 2021

4.0K

[New approaches to target leukemia stem cells].

Katsuto Takenaka, Koichi Akashi

    Nihon Rinsho. Japanese Journal of Clinical Medicine
    |July 15, 2014
    PubMed
    Summary

    Human acute myeloid leukemia (AML) is driven by leukemia stem cells (LSCs). Targeting surface antigens like CD123 on LSCs with monoclonal antibodies shows promise for eradicating these cells and curing AML.

    Area of Science:

    • Hematology
    • Cancer Stem Cell Biology
    • Immunotherapy

    Context:

    • Human acute myeloid leukemia (AML) is characterized by a hierarchical organization maintained by leukemia stem cells (LSCs).
    • LSCs possess self-renewal capabilities, making them crucial for disease initiation and progression.
    • Eradicating LSCs is essential for achieving a cure in AML patients.

    Purpose:

    • To identify and characterize cell surface antigens and signaling pathways specific to AML LSCs.
    • To explore the therapeutic potential of targeting these identified LSC-specific molecules.
    • To evaluate the efficacy of monoclonal antibodies against AML LSCs in preclinical models.

    Summary:

    • AML is driven by leukemia stem cells (LSCs) with self-renewal capacity.

    More Related Videos

    Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
    09:01

    Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

    Published on: March 26, 2018

    13.9K
    Protocol for MicroRNA Transfer into Adult Bone Marrow-derived Hematopoietic Stem Cells to Enable Cell Engineering Combined with Magnetic Targeting
    11:37

    Protocol for MicroRNA Transfer into Adult Bone Marrow-derived Hematopoietic Stem Cells to Enable Cell Engineering Combined with Magnetic Targeting

    Published on: June 18, 2018

    6.2K

    Related Experiment Videos

    Last Updated: Apr 27, 2026

    Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia
    05:24

    Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia

    Published on: February 21, 2021

    4.0K
    Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
    09:01

    Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

    Published on: March 26, 2018

    13.9K
    Protocol for MicroRNA Transfer into Adult Bone Marrow-derived Hematopoietic Stem Cells to Enable Cell Engineering Combined with Magnetic Targeting
    11:37

    Protocol for MicroRNA Transfer into Adult Bone Marrow-derived Hematopoietic Stem Cells to Enable Cell Engineering Combined with Magnetic Targeting

    Published on: June 18, 2018

    6.2K
  • Research has identified specific cell surface antigens (e.g., CD123, CD44, TIM-3, CD47) and signaling pathways on AML LSCs.
  • Monoclonal antibodies targeting these antigens demonstrate efficacy against AML LSCs in xenotransplant models.

    • Impact:

    • Provides insights into LSC biology and potential therapeutic targets for AML.
    • Highlights the promise of antibody-based therapies for eradicating LSCs.
    • Supports the development of novel immunotherapies for acute myeloid leukemia.